American College of Cardiology 2013

American College of Cardiology 2013

ASTRONAUT Study: No Significant Post-Discharge Mortality Benefit Seen with Aliskiren

The results of the ASTRONAUT study revealed that aliskiren did not improve post-discharge mortality and/or hospitalizations when added to standard therapy in recently hospitalized patients with worsening chronic heart failure and reduced ejection fraction, stated Mihai Gheorghiade, MD, from the Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, IL.

Prasugrel Reload Dosing Regimen Reduces High On-Treatment Platelet Reactivity Rates

Patients with acute coronary syndrome on maintenance dose prasugrel had a reduction in high on-treatment platelet reactivity rates after a prasugrel reload strategy, according to a post hoc analysis of a prospective, randomized, open-label pharmacodynamic study presented at ACC.13, the American College of Cardiology’s 62nd Annual Scientific Session.

Positive Thrombotic and Thrombolytic Effects Observed with PAR-1 Antagonist Vorapaxar

Vorapaxar, a novel, oral PAR-1 agonist that inhibits thrombin-induced platelet activation, was found to prolong occlusion time and shorten lysis time, with a favorable effect on thrombotic and thrombolytic status, results of a study presented at ACC.13, the American College of Cardiology’s 62nd Annual Scientific Session, has found.

Novel Omega-3 Free Fatty Acid Formulation Reduces Non-HDL-C in High-Risk Patients on Statins

A novel formulation of omega-3 free fatty acids (OM3-FFA) at a dosage as low as 2g/d was effective and well tolerated in lowering non-high density lipoprotein cholesterol (non-HDL-C), triglycerides (TG), and other markers of cardiovascular risk—including Apo CIII and Lp-PLA2—in patients with persistent hypertriglyceridemia on statin therapy, according to a study presented at ACC.13, the American College of Cardiology’s 62nd Annual Scientific Session.